Nomura Holdings Inc. Has $1.28 Million Stake in Nevro Corp. (NYSE:NVRO)

Nomura Holdings Inc. raised its stake in Nevro Corp. (NYSE:NVRO) by 28.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,250 shares of the medical equipment provider’s stock after buying an additional 13,000 shares during the quarter. Nomura Holdings Inc. owned 0.16% of Nevro worth $1,275,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Assetmark Inc. lifted its stake in Nevro by 30.4% in the fourth quarter. Assetmark Inc. now owns 3,131 shares of the medical equipment provider’s stock valued at $67,000 after buying an additional 730 shares during the period. Natixis Advisors L.P. acquired a new stake in shares of Nevro during the third quarter worth about $248,000. Dark Forest Capital Management LP acquired a new stake in shares of Nevro during the third quarter worth about $329,000. Barclays PLC raised its position in shares of Nevro by 30.6% during the third quarter. Barclays PLC now owns 17,632 shares of the medical equipment provider’s stock worth $339,000 after purchasing an additional 4,133 shares during the period. Finally, Trexquant Investment LP raised its position in shares of Nevro by 116.9% during the third quarter. Trexquant Investment LP now owns 28,893 shares of the medical equipment provider’s stock worth $555,000 after purchasing an additional 15,574 shares during the period. Institutional investors and hedge funds own 95.52% of the company’s stock.

Nevro Stock Down 1.3 %

NVRO stock opened at $8.81 on Thursday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 5.57 and a current ratio of 7.38. The business has a 50 day moving average price of $10.51 and a two-hundred day moving average price of $14.88. Nevro Corp. has a twelve month low of $8.62 and a twelve month high of $26.63.

Nevro (NYSE:NVRO) last posted its quarterly earnings results on Tuesday, May 7th. The medical equipment provider reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.32. Nevro had a negative return on equity of 27.48% and a negative net margin of 19.17%. The firm had revenue of $101.90 million during the quarter, compared to the consensus estimate of $97.90 million. During the same period last year, the company earned ($0.98) earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. On average, sell-side analysts predict that Nevro Corp. will post -2.12 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NVRO. Robert W. Baird dropped their price target on Nevro from $23.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, February 22nd. Citigroup lowered Nevro from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $13.50 to $9.00 in a research report on Wednesday, May 22nd. Oppenheimer lowered Nevro from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 22nd. StockNews.com raised Nevro from a “sell” rating to a “hold” rating in a research report on Friday, March 1st. Finally, Royal Bank of Canada dropped their target price on Nevro from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research report on Monday, April 15th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.46.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.